Fig 2: Effects of miR-124-3p on apoptosis of transplanted tumors in nude mice and expression of FGF2–EGFR signaling pathway-related proteins by targeting MGAT5. (A) Tumor cell apoptosis detected using TUNEL kit (×400); (B) FGF2–EGFR signaling pathway-related protein expression in PC9-MTA tumor tissue detected by Western blot; (C) FGF2–EGFR signaling pathway-related protein expression in H1993-MTA tumor tissue detected by Western blot. *p<0.05 vs Control group; #p<0.05 vs miR-124-3p group.

Fig 3: Dual-luciferase reporter assay system. (A) The expression of MGAT5 protein was detected by Western blotting in PC9-MTA cells. (B) The expression of MGAT5 protein was detected by Western blotting in H1993-MTA cells. (C) Predicted binding sites of miR-124-3p and MGAT5 3'UTR by TargetScan (http://www.targetscan.org). (D) Dual-luciferase reporter results for recombinant vector of miR-124-3p and target gene MGAT5. *p<0.05 compared with control group; #p<0.05, **p<0.01 compared with miR-124-3p group.

Fig 4: Effects of miR-124-3p targeting of MGAT5 on the biological behavior of anti-pemetrexed cells. (A) Expression of MGAT5 mRNA detected by RT-PCR in each group. (B) CCK8 assay to detect cell viability. (C) Colony formation experiment to analyze cell proliferation. (D) Cell apoptosis detected by flow cytometry. Compared with control group, *p<0.05; compared with miR-124-3p group, #p<0.05; compared with sh-NC group, &p<0.05; compared with miR+M-NC group, ^p<0.05.

Fig 5: Effects of miR-124-3p targeting MGAT5 on the expression of FGF2–EGFR signaling pathway-related proteins in PC9-MTA cells (A) and H1993-MTA cells (B). *p<0.05 compared with control group; #p<0.05 compared with miR-124-3p group; &p<0.05 compared with sh-NC group; ^p<0.05 compared with miR+M-NC group.